by Elmets, C.A. et al.
Department of Dermatology, 1530 3rd Ave South, EFH 414, University of Alabama at Birmingham, USA
Department of Dermatology, 1530 3rd Ave South, EFH 414, University of Alabama at Birmingham, USA
After adjusting for age, sex, Fitzpatrick skin type, history of actinic keratosis at randomization, nonmelanoma skin cancer history, and patient time on study, the number of nonmelanoma skin cancers was lower in the celecoxib arm than in the placebo arm (RR = 0.41, 95% CI = 0.23 to 0.72, P = .002) as were the numbers of BCCs (RR = 0.40, 95% CI = 0.18 to 0.93, P = .032) and SCCs (RR = 0.42, 95% CI = 0.19 to 0.93, P = .032).
J. Natl. Cancer Inst. 2010; 24:1835-44
